John Glaspy, MD
Enriched profileProfessor of Medicine, Division of Hematology/Oncology; Co-Chair, Division of Hematology/Oncology; Medical Director, Simms/Mann-UCLA Center for Integrative Oncology · David Geffen School of Medicine
John Glaspy is Professor of Medicine, Division of Hematology/Oncology; Co-Chair, Division of Hematology/Oncology; Medical Director, Simms/Mann-UCLA Center for Integrative Oncology at David Geffen School of Medicine. OpenAlex indexes 724 publications with 38,724 citations (h-index 89); ClinicalTrials.gov lists 15 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
John A. Glaspy, MD, is Professor of Medicine, Division of Hematology/Oncology at David Geffen School of Medicine, UCLA. The public record shows 724 publications with 38,724 citations (h-index 89), centered on Monoclonal and Polyclonal Antibodies Research, Erythropoietin and Anemia Treatment, CAR-T cell therapy research. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 12 companies, 5 NIH-funded awards (1986–2026).
- Most recent indexed publication: 2025 · JCO oncology practice
- Top research focus: Monoclonal and Polyclonal Antibodies Research
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 258.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Sponsor: Jonsson Comprehensive Cancer Center
- Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Sponsor: EVIVE Biotechnology
Industry payments
Updated 27 Aug 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- Daiichi Sankyo Inc.Program year20251 payment
- ARRAY BIOPHARMA INCProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
42.4%PD-1 inhibitor42.2%Pembrolizumab100%Part B, office-administered≥15 patientsAromatase Inhibitor0.2%Anastrozole100%Part D≥14 patientsMetabolism & gastrointestinal
32.7%Other antiemetics27.8%Fosaprepitant100%Part B, office-administered≥15 patientsSerotonin-3 Receptor Antagonist3.7%Palonosetron hcl73%Ondansetron hydrochloride27%Part B, office-administered≥20 patientsMusculoskeletal
22.2%RANK Ligand Inhibitor22.2%Denosumab100%Part B, office-administered≥19 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
5 NIH research awards on record, funded 1986–2026 per NIH RePORTER. The latest:
- Protocol Review and Monitoring System (PRMS)
University of California Los Angeles
FY2026$163,513P30CA016042 - Protocol Review and Monitoring System (PRMS)
University of California Los Angeles
FY2025$163,513P30CA016042
Congress activity
Updated 27 Aug 2026
81 congress contributions (2004–2026) across AACR, ASCO, ASH, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 1323: Preclinical evaluation of target-mediated clearance and alternative payloads in CDH17-directed antibody drug conjugates.
AACR Annual Meeting
AACR2026Co-author - Cancer patients' comfort with artificial intelligence in oncology care and first-round "AI chemo-teach" quality improvement initiatives.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Racial/Ethnic Disparities in Oncology Clinical Trial Participation: Investigator Attitudes, Needs, and Motivation to Improve.
JCO oncology practice
Article2025 - Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial.
American journal of hematology
Clinical Trial2024 - Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
Molecular cancer therapeutics
Article2023 - A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.
Cancer research communications
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)- 01PD-1 blockade induces responses by inhibiting adaptive immune resistance6,639 citations2014
- 02Adjuvant Trastuzumab in HER2-Positive Breast Cancer2,777 citations2011
- 03
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/john-glaspy-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/John-Glaspy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/john-glaspy-a709a45
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/uclajonssoncancercenter/p/CwlCOADsopL
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- MPH
Health Services Administration, UCLA School of Public Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership roles
journal and society appointments- Co-Chair
Division of Hematology/Oncology, UCLA (with Dr. Dennis Slamon)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Chair
Founders Board and UCLA Leadership, Simms/Mann-UCLA Center for Integrative Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Fellow
American College of Physicians
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labusinessjournal.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Jonsson Comprehensive Cancer Center (JCCC)
UCLA, Director, Clinical Research Unit; Director, Women's Cancer Research Program; Vice-Chair, Scientific Protocol Review Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Ronald Reagan UCLA Medical Center / UCLA Medical Center
Santa Monica (clinical practice locations)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labusinessjournal.com ↗
- Q&A: "UCLA Researcher Provides Insight Into the Impact of Pembrolizumab's Approval"
OncLive interview on melanoma immunotherapy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - Recurring contributing author/interviewee
OncLive oncology news and video content
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.